## Johan Askling

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7387945/publications.pdf

Version: 2024-02-01

253 papers 10,362 citations

25014 57 h-index 93 g-index

256 all docs

256 docs citations

times ranked

256

10493 citing authors

#	Article	lF	CITATIONS
1	Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. Gastroenterology, 2002, 123, 1428-1435.	0.6	460
2	Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis and Rheumatism, 2005, 52, 1986-1992.	6.7	378
3	Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Annals of the Rheumatic Diseases, 2005, 64, 1414-1420.	0.5	365
4	Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Annals of the Rheumatic Diseases, 2005, 64, 1421-1426.	0.5	343
5	Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Annals of the Rheumatic Diseases, 2007, 66, 1339-1344.	0.5	296
6	Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet, The, 2020, 395, 123-131.	6.3	262
7	Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: metaâ€analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiology and Drug Safety, 2011, 20, 119-130.	0.9	259
8	Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Annals of the Rheumatic Diseases, 2009, 68, 648-653.	0.5	233
9	Cancer risk in patients with rheumatoid arthritis treated with anti–tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?. Arthritis and Rheumatism, 2009, 60, 3180-3189.	6.7	215
10	Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut, 2005, 54, 617-622.	6.1	189
11	Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Research and Therapy, 2016, 18, 251.	1.6	177
12	Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. European Respiratory Journal, 2016, 48, 1690-1699.	3.1	176
13	Incidence and Treatment of Patients Diagnosed WithÂInflammatory Bowel Diseases at 60 Years or OlderÂinÂSweden. Gastroenterology, 2018, 154, 518-528.e15.	0.6	162
14	Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab. Annals of the Rheumatic Diseases, 2015, 74, 354-360.	0.5	159
15	Lymphoma development in patients with autoimmune and inflammatory disorders – What are the driving forces?. Seminars in Cancer Biology, 2014, 24, 61-70.	4.3	150
16	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Annals of the Rheumatic Diseases, 2017, 76, 386-391.	0.5	150
17	Swedish registers to examine drug safety and clinical issues in RA. Annals of the Rheumatic Diseases, 2006, 65, 707-712.	0.5	139
18	Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins. Annals of the Rheumatic Diseases, 2015, 74, 375-380.	0.5	132

#	Article	IF	CITATIONS
19	Risk of Venous Thromboembolism in Patients With Rheumatoid Arthritis and Association With Disease Duration and Hospitalization. JAMA - Journal of the American Medical Association, 2012, 308, 1350.	3.8	129
20	Long-term intake of dietary long-chain n-3 polyunsaturated fatty acids and risk of rheumatoid arthritis: a prospective cohort study of women. Annals of the Rheumatic Diseases, 2014, 73, 1949-1953.	0.5	129
21	Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study. The Lancet Gastroenterology and Hepatology, 2020, 5, 475-484.	3.7	125
22	Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice. JAMA Internal Medicine, 2017, 177, 1605.	2.6	124
23	Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Research and Therapy, 2017, 19, 102.	1.6	111
24	Adaptation of the Charlson Comorbidity Index for Register-Based Research in Sweden. Clinical Epidemiology, 2021, Volume 13, 21-41.	1.5	111
25	Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014. BMJ, The, 2017, 358, j3951.	3.0	106
26	The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis. Current Opinion in Rheumatology, 2008, 20, 138-144.	2.0	105
27	Association Between RheumatoidÂArthritisÂand Risk of IschemicÂand Nonischemic Heart Failure. Journal of the American College of Cardiology, 2017, 69, 1275-1285.	1.2	102
28	Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. Annals of the Rheumatic Diseases, 2017, 76, 105-111.	0.5	97
29	Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Annals of the Rheumatic Diseases, 2017, 76, 1515-1521.	0.5	92
30	Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ, The, 2016, 352, i262.	3.0	90
31	Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?. Annals of the Rheumatic Diseases, 2017, 76, 364-370.	0.5	88
32	Rheumatoid arthritis is associated with a more severe presentation of acute coronary syndrome and worse short-term outcome. European Heart Journal, 2015, 36, 3413-3422.	1.0	87
33	Pancreatic Cancer Following Acute Pancreatitis: A Population-based Matched Cohort Study. American Journal of Gastroenterology, 2018, 113, 1711-1719.	0.2	87
34	Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Annals of Neurology, 2020, 87, 688-699.	2.8	86
35	Mortality in ankylosing spondylitis: results from a nationwide population-based study. Annals of the Rheumatic Diseases, 2016, 75, 1466-1472.	0.5	83
36	Family history of rheumatoid arthritis: an old concept with new developments. Nature Reviews Rheumatology, 2016, 12, 335-343.	3.5	82

#	Article	IF	Citations
37	Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?. Annals of the Rheumatic Diseases, 2015, 74, 1212-1217.	0.5	81
38	FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease. Nature, 2020, 584, 619-623.	13.7	81
39	TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Annals of the Rheumatic Diseases, 2015, 74, 2137-2143.	0.5	79
40	Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Annals of the Rheumatic Diseases, 2021, 80, 1086-1093.	0.5	79
41	The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Research and Therapy, 2015, 17, 118.	1.6	77
42	Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. Annals of the Rheumatic Diseases, 2017, 76, 2025-2030.	0.5	77
43	Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased?. Arthritis and Rheumatology, 2017, 69, 700-708.	2.9	76
44	Cardiovascular risk factors in nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 197-204.	1.9	75
45	Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Annals of the Rheumatic Diseases, 2006, 65, 1184-1187.	0.5	<b>7</b> 3
46	The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Annals of the Rheumatic Diseases, 2015, 74, 970-978.	0.5	69
47	Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 2087-2094.	0.5	67
48	Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study. Annals of the Rheumatic Diseases, 2016, 75, 1838-1842.	0.5	66
49	Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Annals of the Rheumatic Diseases, 2021, 80, 169-175.	0.5	66
50	No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: Results from two Swedish populationâ€based rheumatoid arthritis cohorts. Arthritis and Rheumatism, 2009, 60, 2861-2869.	6.7	64
51	Prevalence of Periodontitis in Patients with Established Rheumatoid Arthritis: A Swedish Population Based Case-Control Study. PLoS ONE, 2016, 11, e0155956.	1.1	64
52	Gastrointestinal Infection Increases Odds of Inflammatory Bowel Disease in a Nationwide Case–Control Study. Clinical Gastroenterology and Hepatology, 2019, 17, 1311-1322.e7.	2.4	64
53	The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Research and Therapy, 2014, 16, R127.	1.6	63
54	Mediterranean diet and risk of rheumatoid arthritis: a population-based case-control study. Arthritis Research and Therapy, 2018, 20, 175.	1.6	63

#	Article	IF	CITATIONS
55	Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964–2014. Gut, 2020, 69, 453-461.	6.1	62
56	Malignancy and biologic therapy in rheumatoid arthritis. Current Opinion in Rheumatology, 2008, 20, 334-339.	2.0	60
57	How well do ACPA discriminate and predict RA in the general population: a study based on 12â€590 population-representative Swedish twins. Annals of the Rheumatic Diseases, 2017, 76, 119-125.	0.5	60
58	Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden. Annals of the Rheumatic Diseases, 2016, 75, 1272-1278.	0.5	59
59	Sarcoidosis mortality in Sweden: aÂpopulation-based cohort study. European Respiratory Journal, 2018, 51, 1701815.	3.1	59
60	Validation of the rheumatoid arthritis diagnosis in the Swedish National patient register: a cohort study from Stockholm County. BMC Musculoskeletal Disorders, 2014, 15, 432.	0.8	58
61	Treatment response and drug retention rates in 24 195 biologic-na $ ilde{A}^-$ ve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration. Annals of the Rheumatic Diseases, 2019, 78, 1536-1544.	0.5	58
62	Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risks. Annals of the Rheumatic Diseases, 2017, 76, 1642-1647.	0.5	57
63	Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Annals of the Rheumatic Diseases, 2015, 74, 890-896.	0.5	56
64	Increased Mortality of Patients With Childhood-Onset Inflammatory Bowel Diseases, Compared With the GeneralÂPopulation. Gastroenterology, 2019, 156, 614-622.	0.6	55
65	Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis. Annals of Internal Medicine, 2018, 169, 291-299.	2.0	53
66	The Association Between Schizophrenia and Rheumatoid Arthritis: A Nationwide Population-Based Swedish Study on Intraindividual and Familial Risks. Schizophrenia Bulletin, 2014, 40, 1552-1559.	2.3	52
67	Physical activity and risk of rheumatoid arthritis in women: a population-based prospective study. Arthritis Research and Therapy, 2015, 17, 40.	1.6	51
68	Mortality following new-onset Rheumatoid Arthritis: has modern Rheumatology had an impact?. Annals of the Rheumatic Diseases, 2018, 77, 85-91.	0.5	51
69	Familial aggregation and heritability of sarcoidosis: a Swedish nested caseâ^'control study. European Respiratory Journal, 2018, 52, 1800385.	3.1	51
70	Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. Annals of the Rheumatic Diseases, 2019, 78, 320-327.	0.5	50
71	Validity of ankylosing spondylitis and undifferentiated spondyloarthritis diagnoses in the Swedish National Patient Register. Scandinavian Journal of Rheumatology, 2015, 44, 369-376.	0.6	47
72	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 476-479.	0.5	47

#	Article	IF	CITATIONS
73	Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients. Scandinavian Journal of Gastroenterology, 2019, 54, 55-63.	0.6	45
74	Occurrence and relative risk of stroke in incident and prevalent contemporary rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 541-546.	0.5	43
75	Improved performance of epidemiologic and genetic risk models for rheumatoid arthritis serologic phenotypes using family history. Annals of the Rheumatic Diseases, 2015, 74, 1522-1529.	0.5	43
76	Validity of administrative codes associated with cirrhosis in Sweden. Scandinavian Journal of Gastroenterology, 2020, 55, 1205-1210.	0.6	43
77	Risk Factors for the Rapid Increase in Risk of Acute Coronary Events in Patients With Newâ€Onset Rheumatoid Arthritis: A Nested Case–Control Study. Arthritis and Rheumatology, 2015, 67, 2845-2854.	2.9	42
78	How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)?. Scandinavian Journal of Rheumatology, 2015, 44, 22-28.	0.6	41
79	The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of $16$ registries. Rheumatology, $2021$ , $60$ , $820$ - $828$ .	0.9	41
80	Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis. Annals of the Rheumatic Diseases, 2005, 64, 1765-1768.	0.5	40
81	Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed?. Annals of the Rheumatic Diseases, 2015, 74, 648-654.	0.5	38
82	Familial aggregation of arthritis-related diseases in seropositive and seronegative rheumatoid arthritis: a register-based case-control study in Sweden. Annals of the Rheumatic Diseases, 2016, 75, 183-189.	0.5	36
83	Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. Annals of the Rheumatic Diseases, 2018, 77, 650-657.	0.5	36
84	Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden. Annals of the Rheumatic Diseases, 2020, 79, 566-572.	0.5	36
85	Prevalence of paediatric inflammatory bowel disease in Sweden: a nationwide population-based register study. BMC Gastroenterology, 2017, 17, 23.	0.8	35
86	Risk of cardiac rhythm disturbances and aortic regurgitation in different spondyloarthritis subtypes in comparison with general population: a register-based study from Sweden. Annals of the Rheumatic Diseases, 2018, 77, 541-548.	0.5	34
87	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. Annals of the Rheumatic Diseases, 2019, 78, 1160-1166.	0.5	34
88	Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open, 2020, 6, e001280.	1.8	33
89	Rheumatoid arthritis registries in Sweden. Clinical and Experimental Rheumatology, 2005, 23, S195-200.	0.4	33
90	Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 85-93.	1.4	32

#	Article	IF	CITATIONS
91	Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Rheumatology, 2022, 61, 1810-1818.	0.9	31
92	Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work?. Annals of the Rheumatic Diseases, 2017, 76, 1245-1252.	0.5	29
93	Malignancy and rheumatoid arthritis. Current Rheumatology Reports, 2007, 9, 421-426.	2.1	28
94	Occupational exposure to asbestos and silica and risk of developing rheumatoid arthritis: findings from a Swedish population-based case-control study. RMD Open, 2019, 5, e000978.	1.8	28
95	Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors. Annals of the Rheumatic Diseases, 2020, 79, 581-586.	0.5	28
96	Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration. Annals of the Rheumatic Diseases, 2021, 80, 1410-1418.	0.5	28
97	Is History of Squamous-Cell Skin Cancer a Marker of Poor Prognosis in Patients with Cancer?. Annals of Internal Medicine, 1999, 131, 655.	2.0	26
98	Risk of non-Hodgkin's lymphoma following tuberculosis. British Journal of Cancer, 2001, 84, 113-115.	2.9	26
99	Risk of first and recurrent serious infection in sarcoidosis: a Swedish register-based cohort study. European Respiratory Journal, 2020, 56, 2000767.	3.1	26
100	Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset. Annals of the Rheumatic Diseases, 2022, 81, 1085-1095.	0.5	26
101	Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme. RMD Open, 2017, 3, e000498.	1.8	25
102	Juvenile onset arthritis and pregnancy outcome: a population-based cohort study. Annals of the Rheumatic Diseases, 2017, 76, 1809-1814.	0.5	25
103	Respiratory Diseases as Risk Factors for Seropositive and Seronegative Rheumatoid Arthritis and in Relation to Smoking. Arthritis and Rheumatology, 2021, 73, 61-68.	2.9	25
104	Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study. RMD Open, 2018, 4, e000762.	1.8	24
105	Inflammatory bowel disease and risk of small bowel cancer: a binational population-based cohort study from Denmark and Sweden. Gut, 2021, 70, gutjnl-2020-320945.	6.1	23
106	Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register. Scandinavian Journal of Rheumatology, 2015, 44, 431-437.	0.6	22
107	Biological treatment in ankylosing spondylitis in the Nordic countries during 2010–2016: a collaboration between five biological registries. Scandinavian Journal of Rheumatology, 2018, 47, 465-474.	0.6	22
108	Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register. Rheumatology, 2019, 58, 1367-1377.	0.9	22

#	Article	IF	Citations
109	Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. RMD Open, 2018, 4, e000655.	1.8	21
110	Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs—a Swedish cohort study of risks by time, drug and lymphoma subtype. Rheumatology, 2021, 60, 809-819.	0.9	21
111	Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?. Annals of the Rheumatic Diseases, 2021, 80, 1445-1452.	0.5	21
112	Anti–Citrullinated Protein Antibody Specificities, Rheumatoid Factor Isotypes, and Incident Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2020, 72, 1658-1667.	2.9	20
113	Is Nephrolithiasis an Unrecognized Extra-Articular Manifestation in Ankylosing Spondylitis? A Prospective Population-Based Swedish National Cohort Study with Matched General Population Comparator Subjects. PLoS ONE, 2014, 9, e113602.	1.1	19
114	Cervical neoplasia in systemic lupus erythematosus: a nationwide study. Rheumatology, 2017, 56, kew459.	0.9	19
115	Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice. Arthritis Research and Therapy, 2019, 21, 128.	1.6	19
116	Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study. Rheumatology, 2021, 60, 2725-2734.	0.9	19
117	How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. Annals of the Rheumatic Diseases, 2016, 75, 1789-1796.	0.5	18
118	Surgical Treatment in Childhood-onset Inflammatory Bowel Disease–A Nationwide Register-based Study of 4695 Incident Patients in Sweden 2002-2014. Journal of Crohn's and Colitis, 2018, 12, 157-166.	0.6	17
119	Risk of Thyroxine-Treated Autoimmune Thyroid Disease Associated With Disease Onset in Patients With Rheumatoid Arthritis. JAMA Network Open, 2018, 1, e183567.	2.8	17
120	Sick Leave and Disability Pension in Prevalent Patients With Crohn's Disease. Journal of Crohn's and Colitis, 2018, 12, 1418-1428.	0.6	17
121	Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naÃve patients with spondyloarthritis. RMD Open, 2019, 5, e001079.	1.8	17
122	Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data. Rheumatology, 2022, 61, 3952-3962.	0.9	17
123	Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries. Arthritis Care and Research, 2015, 67, 1637-1645.	1.5	16
124	Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. Annals of the Rheumatic Diseases, 2016, 75, 1797-1805.	0.5	16
125	Work Loss Before and After Diagnosis of Crohn's Disease. Inflammatory Bowel Diseases, 2019, 25, 1237-1247.	0.9	16
126	Population-based study of patients with primary Sjögren's syndrome and lymphoma: lymphoma subtypes, clinical characteristics, and gender differences. Scandinavian Journal of Rheumatology, 2020, 49, 225-232.	0.6	16

#	Article	IF	Citations
127	Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: A retrospective †target trial' emulated with Swedish realâ€world data. Respirology, 2021, 26, 452-460.	1.3	16
128	Childhood hospitalisation with infections and later development of ankylosing spondylitis: a national case-control study. Arthritis Research and Therapy, 2016, 18, 240.	1.6	15
129	What is the impact of chronic systemic inflammation such as rheumatoid arthritis on mortality following cancer?. Annals of the Rheumatic Diseases, 2016, 75, 862-866.	0.5	15
130	<scp>Oneâ€Year</scp> Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses. Arthritis Care and Research, 2022, 74, 748-758.	1.5	15
131	Hepatobiliary Cancer Risk in Patients with Inflammatory Bowel Disease: A Scandinavian Population-Based Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 886-894.	1.1	15
132	Seropositivity combined with smoking is associated with increased prevalence of periodontitis in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212091.	0.5	15
133	Long-term outcomes and secondary prevention after acute coronary events in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 2017-2024.	0.5	14
134	Comparison of patients with and without pre-existing lymphoma at diagnosis of primary Sjögren's syndrome. Scandinavian Journal of Rheumatology, 2019, 48, 207-212.	0.6	14
135	Adult height in patients with childhoodâ€onset inflammatory bowel disease: a nationwide populationâ€based cohort study. Alimentary Pharmacology and Therapeutics, 2020, 51, 789-800.	1.9	14
136	Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis. Rheumatology, 2021, 60, 3635-3645.	0.9	14
137	Does a family history of RA influence the clinical presentation and treatment response in RA?. Annals of the Rheumatic Diseases, 2016, 75, 1120-1125.	0.5	13
138	Risk and predictors of heart failure in sarcoidosis in a population-based cohort study from Sweden. Heart, 2022, 108, 467-473.	1.2	13
139	Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD Open, 2021, 7, e001987.	1.8	13
140	Oral Contraceptive Use and Risk of Ulcerative Colitis Progression: A Nationwide Study. American Journal of Gastroenterology, 2016, 111, 1614-1620.	0.2	12
141	Uptake of rheumatology biosimilars in the absence of forced switching. Expert Opinion on Biological Therapy, 2018, 18, 499-504.	1.4	12
142	Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validation. RMD Open, 2018, 4, e000771.	1.8	12
143	Are infectious diseases risk factors for sarcoidosis or a result of reverse causation? Findings from a population-based nested case–control study. European Journal of Epidemiology, 2020, 35, 1087-1097.	2.5	12
144	Effects of Childhood-onset Inflammatory Bowel Disease on School Performance: A Nationwide Population-based Cohort Study Using Swedish Health and Educational Registers. Inflammatory Bowel Diseases, 2019, 25, 1663-1673.	0.9	11

#	Article	IF	Citations
145	Morbidity, risk of cancer and mortality in 3645 <i>HFE</i> hi> mutations carriers. Liver International, 2021, 41, 545-553.	1.9	11
146	Age determines the risk of familial inflammatory bowel diseaseâ€"A nationwide study. Alimentary Pharmacology and Therapeutics, 2022, 56, 491-500.	1.9	11
147	Possible Interaction Between Cigarette Smoking and HLA-DRB1 Variation in the Risk of Follicular Lymphoma. American Journal of Epidemiology, 2017, 185, 681-687.	1.6	10
148	Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapies. RMD Open, 2019, 5, e001055.	1.8	9
149	Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study. RMD Open, 2020, 6, e001201.	1.8	9
150	Adult-onset inflammatory bowel disease and rate of serious infections compared to the general population: a nationwide register-based cohort study 2002–2017. Scandinavian Journal of Gastroenterology, 2021, 56, 1152-1162.	0.6	9
151	Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries. Annals of the Rheumatic Diseases, 2022, 81, 789-797.	0.5	9
152	Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply. Rheumatology, 2019, 58, 1510-1511.	0.9	8
153	How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers. RMD Open, 2020, 6, e001363.	1.8	8
154	Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors – a Nordic cohort study. Rheumatology, 2021, 60, 3656-3668.	0.9	8
155	Validation and characterization of venous thromboembolism diagnoses in the Swedish National Patient Register among patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2023, 52, 111-117.	0.6	8
156	A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study. Arthritis Research and Therapy, 2016, 18, 288.	1.6	7
157	Women's earnings are more affected by inflammatory bowel disease than men's: a register-based Swedish cohort study. Journal of Crohn's and Colitis, 2020, 15, 980-987.	0.6	7
158	>Work Loss in Relation to Pharmacological and Surgical Treatment for Crohn's Disease: A Population-Based Cohort Study. Clinical Epidemiology, 2020, Volume 12, 273-285.	1.5	7
159	Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14Â868 patients with spondyloarthritis. Rheumatology, 2020, 59, 2455-2461.	0.9	7
160	Characteristics and outcome of a first acute myocardial infarction in patients with ankylosing spondylitis. Clinical Rheumatology, 2021, 40, 1321-1329.	1.0	7
161	Tuberculosis in Biologic-na $\tilde{A}$ -ve Patients With Rheumatoid Arthritis: Risk Factors and Tuberculosis Characteristics. Journal of Rheumatology, 2021, 48, 1243-1250.	1.0	7
162	European bio-na $\tilde{A}$ -ve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response. Rheumatology, 2022, 61, 3799-3807.	0.9	7

#	Article	IF	Citations
163	Comparison of treatment retention of originator <i>vs</i> biosimilar products in clinical rheumatology practice in Sweden. Rheumatology, 2022, 61, 3596-3605.	0.9	7
164	Validity of clinical psoriatic arthritis diagnoses made by rheumatologists in the Swedish National Patient Register. Scandinavian Journal of Rheumatology, 2023, 52, 374-384.	0.6	7
165	The risk of malignancies in RA patients treated with biologics. Zeitschrift Fur Rheumatologie, 2010, 69, 774-779.	0.5	6
166	Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. Pharmacoepidemiology and Drug Safety, 2015, 24, 1121-1132.	0.9	6
167	Leukemia and Myelodysplastic Syndrome in Granulomatosis with Polyangiitis: Subtypes, Clinical Characteristics, and Outcome. Journal of Rheumatology, 2015, 42, 690-694.	1.0	6
168	Does disease activity at start of biologic therapy influence work-loss in RA patients?. Rheumatology, 2016, 55, 729-734.	0.9	6
169	Perinatal characteristics, older siblings, and risk of ankylosing spondylitis: a case–control study based on national registers. Arthritis Research and Therapy, 2016, 18, 16.	1.6	6
170	Siblings of patients with rheumatoid arthritis are at increased risk of acute coronary syndrome. Annals of the Rheumatic Diseases, 2019, 78, 683-687.	0.5	6
171	Does autoimmune thyroid disease affects rheumatoid arthritis disease activity or response to methotrexate?. RMD Open, 2020, 6, e001282.	1.8	6
172	Comorbidities at diagnosis of rheumatoid arthritis: a population-based case-control study. Rheumatology, 2021, 60, 3760-3769.	0.9	6
173	Risk of acute myocardial infarction in sarcoidosis: A population-based cohort study from Sweden. Respiratory Medicine, 2021, 188, 106624.	1.3	6
174	Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?. Annals of the Rheumatic Diseases, 2022, 81, 433-439.	0.5	6
175	The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. Rheumatology, 2022, 61, 4741-4751.	0.9	6
176	Association Between Inflammatory Bowel Disease and Spondyloarthritis: Findings from a Nationwide Study in Sweden. Journal of Crohn's and Colitis, 2022, 16, 1540-1550.	0.6	6
177	Effectiveness of a Second Biologic After Failure of a Non–tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis. Journal of Rheumatology, 2021, 48, 1512-1518.	1.0	5
178	Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: aÂNordic population-based cohort study. Rheumatology, 2021, 60, 140-146.	0.9	4
179	Surgical interventions for nephrolithiasis in ankylosing spondylitis and the general population. Scandinavian Journal of Urology, 2015, 49, 486-491.	0.6	3
180	Transmission of rheumatoid arthritis through blood transfusion: a retrospective cohort study. Annals of the Rheumatic Diseases, 2018, 77, 1536-1537.	0.5	3

#	Article	IF	CITATIONS
181	Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply. Rheumatology, 2019, 58, 1507-1509.	0.9	3
182	POSO027â€SECULAR TRENDS IN BASELINE CHARACTERISTICS, TREATMENT RETENTION AND RESPONSE RATES 27189 BIO-NAÃVE AXIAL SPONDYLOARTHRITIS PATIENTS INITIATING TNFI – RESULTS FROM THE EUROSPA COLLABORATION. Annals of the Rheumatic Diseases, 2021, 80, 217-218.	IN 0.5	3
183	Allergic conditions and risk of rheumatoid arthritis: a Swedish case–control study. RMD Open, 2022, 8, e002018.	1.8	3
184	SAT0140â€The risk of acute coronary syndromes in RA in relation to TNF inhibitors and risks in the general population: A national cohort study. Annals of the Rheumatic Diseases, 2013, 71, 518.3-519.	0.5	2
185	No association between rheumatoid arthritis, amyotrophic lateral sclerosis, and tumour necrosis factor inhibitor treatment. Annals of the Rheumatic Diseases, 2014, 73, 2061-2062.	0.5	2
186	Does disease activity at the start of biologic therapy influence health care costs in patients with RA?. Rheumatology, 2015, 54, 1472-1477.	0.9	2
187	A3.07â€How well do acpa discriminate and predict ra in the general population -–Âa study based on 12,590 population-representative swedish twins. Annals of the Rheumatic Diseases, 2016, 75, A35.1-A35.	0.5	2
188	Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2018, 47, 270-275.	0.6	2
189	OP0122â€COMPARATIVE EFFECTIVENESS OF JAKI VERSUS BDMARDS; A NATIONWIDE STUDY IN RA. Annals of the Rheumatic Diseases, 2021, 80, 68.2-68.	0.5	2
190	OP0082â€Infections of The Gut, Urogenital and Respiratory Tract and Appendicitis during Childhood, and The Risk of Developing Ankylosing Spondylitis. Annals of the Rheumatic Diseases, 2016, 75, 85.2-86.	0.5	2
191	Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration. Rheumatology, 2022, 61, 4286-4296.	0.9	2
192	The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries. Rheumatology, 2022, 61, 3647-3656.	0.9	2
193	Efficacy of TNF switch after failure of one TNF inhibitor – results from a nation-wide observational study: Table 1. Annals of the Rheumatic Diseases, 2012, 71, A14-A15.	0.5	1
194	FRIO166â€Does biological therapy alter the lymphoma risk or distribution of lymphoma subtypes in patients with ra?. Annals of the Rheumatic Diseases, 2013, 72, A427.2-A427.	0.5	1
195	SAT0098 Validity of Ankylosing Spondylitis and Spondyloarthritis Diagnoses in the Swedish National Patient Register. Annals of the Rheumatic Diseases, 2014, 73, 625.3-626.	0.5	1
196	A10.16â€Risk for lung cancer in ra and different ra phenotypes: Results from a population-based case-control study. Annals of the Rheumatic Diseases, 2016, 75, A79.1-A79.	0.5	1
197	OP0240â€How strong are the associations of spondyloarthritis-related comorbidities with ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis? a register-based study from sweden., 2017,,.		1
198	Correspondence for "Clinical epidemiology of familial sarcoidosis: A systematic literature review― Respiratory Medicine, 2019, 160, 105696.	1.3	1

#	Article	IF	CITATIONS
199	OP0005â€INCIDENCE OF OVERALL AND SITE-SPECIFIC CANCERS IN TNF INHIBITOR TREATED PATIENTS WITH PSORIATIC ARTHRITIS: A POPULATION-BASED COHORT STUDY FROM 4 NORDIC COUNTRIES. , 2019, , .		1
200	Siblings of patients with rheumatoid arthritis have an increased mortality rate: a Swedish cohort study. RMD Open, 2020, 6, e001197.	1.8	1
201	Concordance in survival among firstâ€degree relatives diagnosed with indolent lymphoid malignancies including chronic lymphocytic leukemia. European Journal of Haematology, 2020, 105, 779-785.	1.1	1
202	OP14 Risk of colorectal cancer diagnosis and colorectal cancer mortality in Crohn's disease: A Scandinavian population-based cohort study. Journal of Crohn's and Colitis, 2020, 14, S013-S014.	0.6	1
203	Social stressors and risk of rheumatoid arthritis and their relationship to known modifiable risk factors: results from the Swedish EIRA study. Scandinavian Journal of Rheumatology, 2021, 50, 178-182.	0.6	1
204	Response to: â€~Correspondence on â€~Risk of venous thromboembolism in rheumatoid arthritis and its association with disease activity: a nationwide cohort study from Sweden'' by Zervouet al. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2021-219920.	0.5	1
205	SAT0069â€TUBERCULOSIS IN BIOLOGIC-NAÃVE PATIENTS WITH RHEUMATOID ARTHRITIS - RISK FACTORS AND TUBERCULOSIS CHARACTERISTICS. Annals of the Rheumatic Diseases, 2020, 79, 969.2-969.	0.5	1
206	Reply: Survival in Crohn's disease-associated small bowel adenocarcinoma. Gut, 2021, 70, 998.2-998.	6.1	1
207	Is rheumatoid arthritis a risk factor for acute coronary syndrome also among individuals at elevated risk, such as individuals presenting with acute chest pain?. RMD Open, 2020, 6, e001463.	1.8	1
208	Rheumatoid arthritis autoantibodies and their association with age and sex. Clinical and Experimental Rheumatology, 2021, 39, 879-882.	0.4	1
209	OP0171â€Screening for Anti-CCP in a Large Population Based Cohort and its Association with Prevalent Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A110.3-A111.	0.5	O
210	OPO189â€Long term work disability in anti-TNF therapy treated patients with psoriatic arthritis: A population-based cohort study. Annals of the Rheumatic Diseases, 2013, 71, 118.3-119.	0.5	0
211	SAT0232 Lymphoma in patients with primary sjögren's syndrome: A population-based study of lymphoma subtypes, risk factors and survival. Annals of the Rheumatic Diseases, 2013, 71, 550.2-550.	<sup>9</sup> 0.5	O
212	THU0218â€Hematological malignancies (other than lymphoma) in patients with granulomatous polyangiitis (wegener). Annals of the Rheumatic Diseases, 2013, 71, 229.1-229.	0.5	O
213	THU0182â€Tumour Necrosis Factor Inhibitors and the Risk of Acute Coronary Syndromes in Rheumatoid Arthritis Patients. Annals of the Rheumatic Diseases, 2014, 73, 244.2-244.	0.5	O
214	THU0410â€When Does the Female Predominance in RA Start – Does Sex Influence the Risk of ACPA Development?. Annals of the Rheumatic Diseases, 2014, 73, 323.2-324.	0.5	o
215	THU0081â€Pregnancy Outcome in Patients with Ankylosing Spondylitis – A National Register Study: Table 1 Annals of the Rheumatic Diseases, 2014, 73, 205.1-205.	0.5	o
216	THU0095â€Is Nephrolithiasis an Unrecognized Extra-Articular Manifestation in Ankylosing Spondylitis? A Prospective Population-Based National Cohort Study with Matched General Population Comparator Subjects. Annals of the Rheumatic Diseases, 2014, 73, 209.2-209.	0.5	O

#	Article	IF	CITATIONS
217	AB1105â€Epidemiological Assessment of Baseline Characteristics of the Abatacept-Treated Patients in Select Real-World Rheumatoid Arthritis Data Sources. Annals of the Rheumatic Diseases, 2014, 73, 1167.2-1167.	0.5	0
218	FRIO202â€Does Disease Activity at Start of Biologic Therapy Influence Productivity Losses in Patients with Ra?. Annals of the Rheumatic Diseases, 2014, 73, 456.1-456.	0.5	0
219	AB0118â€Physical Activity and Risk of Rheumatoid Arthritis in Women. Annals of the Rheumatic Diseases, 2014, 73, 843.1-843.	0.5	O
220	OP0275â€Birth Characteristics and Childhood Infections Predict Ankylosing Spondylitis. A National Register Based Nested Case-Control Study. Annals of the Rheumatic Diseases, 2015, 74, 176.1-176.	0.5	0
221	FRI0596â€Rheumatoid Arthritis Risk Alleles, Hla-Drb1 Haplotypes, and Response To TNFI Therapy – Results from A Swedish Cohort Study. Annals of the Rheumatic Diseases, 2016, 75, 658.1-658.	0.5	0
222	FRIO136â€Risk for Lung Cancer in RA and Different RA Phenotypes: Results from A Population-Based Case-Control Study. Annals of the Rheumatic Diseases, 2016, 75, 477.2-477.	0.5	0
223	SATO309â€Primary Sjögren's Syndrome and Lymphoma – A Population-Based Study Focused on Lymphoma as Exclusion Criterion for Primary Sjögren's Syndrome Diagnosis. Annals of the Rheumatic Diseases, 2016, 75, 779.3-780.	0.5	0
224	OP0189â€Rate of Cervical Neoplasia in Systemic Lupus Erythematosus: A Nationwide Cohort-Study: Table 1. Annals of the Rheumatic Diseases, 2016, 75, 128.2-128.	0.5	0
225	SAT0669â€How do we use biologics in patients with a history of malignancy? an assessment of treatment patterns using scandinavian registers. , 2017, , .		0
226	OP0100â€Overall cancer risk in patients with rheumatoid arthritis treated with tnf inhibitors, tocilizumab, abatacept, or rituximab., 2017,,.		0
227	OP0308â€Tnf inhibitor treatment and risk of cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study from sweden. , 2017, , .		O
228	THU0652â€Assessment of biosimilars using real world data: the complexity of choosing a comparator and understanding uptake. , 2017, , .		0
229	OP0016 $\hat{a}\in$ Comparative effectiveness at 1 year of different ANTI-TNF drugs as first biologic dmard in patients with rheumatoid arthritis $\hat{a}\in$ " results from the nationwide swedish register., 2017,,.		0
230	SAT0535â€Eular 2018 core set of data to be collected in giant cell arteritis registries and databases viewpoints from a eular task force. , 2018, , .		0
231	774â€Occupational exposure to combustion products and risk of developing rheumatoid arthritis. , 2018, , .		0
232	P5423Rheumatoid arthritis as an emergency department risk factor for acute coronary syndrome. European Heart Journal, 2018, 39, .	1.0	0
233	SAT0046â€ARE SENSE OF SOCIAL SUPPORT AND LOW DECISION LATITUDE AT WORK LINKED TO RISK OF RHEUMATOID ARTHRITIS, AND IF SO, HOW DO THEY RELATE TO OTHER RISK FACTORS? RESULTS FROM THE SWEDISH EIRA STUDY. , 2019, , .		0
234	OP0261â€RISK OF NEUROLOGICAL ADVERSE EVENTS DURING TUMOUR NECROSIS FACTOR INHIBITOR TREATMENT FOR ARTHRITIS: A POPULATION-BASED COHORT STUDY FROM DANBIO AND ARTIS. , 2019, , .		0

#	Article	IF	CITATIONS
235	AB1285â€IGA RF IS ASSOCIATED WITH HIGH AGE OF RHEUMATOID ARTHRITIS ONSET. , 2019, , .		0
236	THU0066â $\in$ IN EARLY RHEUMATOID ARTHRITIS ANTI-CITRULLINATED PEPTIDE ANTIBODIES ASSOCIATE WITH LOWER NUMBER OF AFFECTED JOINTS, AND IGM RHEUMATOID FACTOR WITH SYSTEMIC INFLAMMATION IN AN ANTI-CITRULLINE DEPENDENT MANNER. , 2019, , .		0
237	THU0090 $\hat{a}$ $\in$ MORTALITY OVER UP TO 14 YEARS FOLLOW-UP IN MTX-REFRACTORY PATIENTS RANDOMIZED TO A STRATEGY STARTING WITH ADDITION OF INFLIXIMAB OR ADDITION OF SULFASALAZINE AND HYDROXYCHLOROQUINE. , 2019, , .	A.	O
238	SAT0317â€INCIDENCE OF EXTRA-ARTICULAR MANIFESTATIONS IN ANKYLOSING SPONDYLITIS, PSORIATIC ARTHRITIS AND UNDIFFERENTIATED SPONDYLOARTHRITIS – RESULTS FROM A NATIONAL REGISTER-BASED COHORT STUDY. , 2019, , .		O
239	Response to: â€~Inflammatory and non-inflammatory triggers of acute coronary syndromes' by Eyuboglu. Annals of the Rheumatic Diseases, 2020, 79, e50-e50.	0.5	O
240	Response to: â€~Neuroinflammatory events after anti-TNFα therapy' by Kaltsonoudiset al. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-217802.	0.5	0
241	OP08 Inflammatory bowel disease and risk of small bowel cancer: A binational population-based cohort study from Denmark and Sweden. Journal of Crohn's and Colitis, 2020, 14, S007-S010.	0.6	0
242	Mortality over 14 years in MTX-refractory patients randomized to a strategy of addition of infliximab or sulfasalazine and hydroxychloroquine. Rheumatology, 2021, 60, 2217-2222.	0.9	0
243	OP0140â€BIOLOGIC REFRACTORY DISEASE IN AXIAL SPONDYLOARTHRITIS - DEFINITION, PREVALENCE AND PATIENT CHARACTERISTICS. A COLLABORATION BETWEEN FIVE NORDIC BIOLOGIC REGISTRIES. Annals of the Rheumatic Diseases, 2021, 80, 82-83.	0.5	O
244	AB0122â€THE NORA PROJECT - PREDICTION OF THERAPY RESPONSE IN RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 1090.2-1090.	0.5	0
245	OP0218â€MORTALITY IN PATIENTS WITH PSORIATIC ARTHRITIS IN SWEDEN. Annals of the Rheumatic Diseases, 2021, 80, 130.1-131.	0.5	O
246	POSO484â€THE ASSOCIATION BETWEEN SOCIAL STRESSORS AND DISEASE REMISSION AMONG MEN AND WOMEN WITH EARLY RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases, 2021, 80, 474-475.	0.5	0
247	Comment on: Incidence of extra-articular manifestations in AS, PsA and undifferentiated SpA: results from a national register-based cohort study. Reply. Rheumatology, 2021, , .	0.9	O
248	Lymphomas in Rheumatoid Arthritis Patients Treated with Anti-TNF Therapy: A Report from the Swedish Biologics Register (ARTIS) and the ARTIS Study Group 1998–2006. Blood, 2008, 112, 3754-3754.	0.6	0
249	Analysis of ACPA positivity and ACPA fine specificities in a large Swedish twin cohort (TwinGene). Annals of the Rheumatic Diseases, 2012, 71, A23.2-A24.	0.5	O
250	OP0023â€Effect of anterior uveitis, psoriasis and inflammatory bowel disease on drug-survival for tnf-inhibitors in ankylosing spondylitis. , 2018, , .		0
251	OP0024â€What happens to patients with ankylosing spondylitiswho start a first biologic? a swedish study of treatment trajectories in clinical practice. , 2018, , .		O
252	OP0231â€Gastro-intestinal perforations among rheumatoid arthritis patients treated with biologic dmards: a nationwide swedish cohort study. , 2018, , .		0

# ARTICLE IF CITATIONS

253 THU0243â€...Case fatality over 365 days after first acute coronary syndrome in patients with ankylosing spondylitis., 2018,,... o